Nicholas Investment Partners, LP - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 265 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2022. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.

Quarter-by-quarter ownership
Nicholas Investment Partners, LP ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q3 2023$17,479,008
-44.7%
335,554
-32.8%
1.30%
-39.7%
Q2 2023$31,628,530
+44.5%
499,503
+20.8%
2.16%
+12.8%
Q4 2022$21,882,790
+20.4%
413,507
+5.8%
1.92%
+13.8%
Q3 2022$18,178,000
-26.6%
390,678
-10.0%
1.68%
-28.0%
Q2 2022$24,770,000
-28.0%
433,959
-22.8%
2.34%
-4.4%
Q1 2022$34,412,000
+0.7%
562,373
-13.9%
2.45%
+13.2%
Q4 2021$34,172,000
+49.5%
652,886
+6.5%
2.16%
+29.6%
Q3 2021$22,861,000
-6.4%
613,212
+2.5%
1.67%
+8.9%
Q2 2021$24,421,000
+29.8%
598,261
+7.9%
1.53%
+16.8%
Q1 2021$18,816,000
+51.6%
554,545
+42.1%
1.31%
+36.8%
Q4 2020$12,411,000
+5.7%
390,289
-14.7%
0.96%
-24.5%
Q3 2020$11,745,000
+1685.0%
457,720
+960.0%
1.27%
+2786.4%
Q3 2016$658,000
-63.5%
43,181
-6.9%
0.04%
-64.8%
Q2 2016$1,801,000
+592.7%
46,400
+470.7%
0.12%
+635.3%
Q2 2015$260,0008,1300.02%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q2 2022
NameSharesValueWeighting ↓
TANG CAPITAL MANAGEMENT LLC 700,000$42,833,0008.57%
SILVERARC CAPITAL MANAGEMENT, LLC 308,819$18,897,0007.82%
Vahanian & Associates Financial Planning Inc. 45,533$2,786,0006.44%
DCF Advisers, LLC 238,500$14,594,0006.39%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 50,956$20,930,0004.72%
SUVRETTA CAPITAL MANAGEMENT, LLC 1,531,923$93,738,0002.86%
Nicholas Investment Partners, LP 562,373$34,412,0002.45%
Bellevue Group AG 3,429,619$209,859,0002.44%
WASATCH ADVISORS LP 7,477,868$457,571,0002.25%
Quantum Private Wealth, LLC 73,772$4,514,0001.95%
View complete list of INTRA CELLULAR THERAPIES INC shareholders